<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04059913</url>
  </required_header>
  <id_info>
    <org_study_id>FGCL-4592-818</org_study_id>
    <nct_id>NCT04059913</nct_id>
  </id_info>
  <brief_title>Evaluate the Efficacy and Safety of Multiple Roxadustat Dosing Regimens for the Treatment of Anemia in Dialysis Subjects With Chronic Kidney Disease</brief_title>
  <official_title>A Prospective, Randomized, Open-Label, Multi-Center Study to Evaluate the Efficacy and Safety of Multiple Roxadustat Dosing Regimens for the Treatment of Anemia in Dialysis Subjects With Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FibroGen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FibroGen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open-label, multi-center study in dialysis CKD subjects to evaluate the
      efficacy and relative safety of different dosing regimens of roxadustat over a 36-week
      treatment period.

      There are three study periods:

        -  Screening Period (up to 4 weeks)

        -  Treatment Period (36 weeks)

      Part 1: Correction/Conversion Period (weeks 1-20)

      Part 2: Hemoglobin (Hb) Maintenance Period (weeks 21-36)

        -  Follow-up Period (4 weeks)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 102 ESA-naïve subjects and 204 ESA-treated subjects will be enrolled and
      randomized respectively in a 1:1 ratio to receive roxadustat at one of two starting doses as
      below:

        -  Low weight-based dosing: 70 mg TIW for body weight &lt; 60 kg or 100 mg TIW for body weight
           ≥ 60 kg

        -  Standard weight-based dosing: 100 mg TIW for body weight &lt; 60 kg or 120 mg TIW for body
           weight ≥ 60 kg

      After 20 weeks of treatment, all eligible subjects whose last two Hb levels ≥ 10.5 g/dL AND
      change in Hb over most recent 4 weeks is &gt; - 10 g/dL will switch to receive roxadustat for
      another 16 weeks to evaluate the efficacy and safety of new dosing regimens.

      At end of Week 36, all subjects will discontinue roxadustat and enter a 4-week Follow-up
      Period.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 11, 2019</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1 (Weeks 1-20): to descriptively compare efficacy of 2 starting doses</measure>
    <time_frame>Weeks 1-21</time_frame>
    <description>ESA-naïve: the proportion of subjects who achieve Hb ≥ 11.0 g/dL in the first 20 weeks
ESA-treated: the proportion of subjects who achieve mean Hb ≥ 10.0 g/dL averaged over Week 17 visit to Week 21 visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 (Weeks 21-36): to compare efficacy of roxadustat at different frequencies</measure>
    <time_frame>Weeks 33-37</time_frame>
    <description>• Mean Hb averaged at Weeks 33-37 visits</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change in Hb level from baseline to average over Weeks 17- 21 visits</measure>
    <time_frame>Weeks 17-21</time_frame>
    <description>Part 1 - Secondary analyses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ESA-naïve: the proportion of subjects with mean Hb (averaged Week 17 to 21 visits) ≥ 10 g/dL</measure>
    <time_frame>Weeks 17-21</time_frame>
    <description>Part 1 - Secondary analyses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with mean Hb (averaged Weeks 33 to 37 visits) ≥ 10 g/dL</measure>
    <time_frame>Weeks 33-37</time_frame>
    <description>Part 2 - Secondary analyses</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of dose adjustments during Part 1;</measure>
    <time_frame>Weeks 1-21</time_frame>
    <description>Additional analyses</description>
  </other_outcome>
  <other_outcome>
    <measure>ESA-naïve: time to achieving Hb ≥ 10.5 g/dL</measure>
    <time_frame>Weeks 1-21</time_frame>
    <description>Additional analyses</description>
  </other_outcome>
  <other_outcome>
    <measure>ESA-treated: the proportion of scheduled Hb values ≥ 10.0 g/dL</measure>
    <time_frame>Weeks 1-21</time_frame>
    <description>Additional analyses</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">306</enrollment>
  <condition>CKD Anemia in Dialysis Patients</condition>
  <arm_group>
    <arm_group_label>Part 1 (2 arms) and Part 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The purpose of Part 1 is to evaluate difference between low and standard weight-based doses and Part 2 is to evaluate the difference among dosing frequencies</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Part 1:
Arm Type: Other
Arm Title: Low weight-based dosing
Arm 1: Low weight-based dosing
Arm Description: Subjects in this arm will receive roxadustat 70 mg three times a week (TIW) for body weight &lt; 60 kg or 100 mg TIW for body weight ≥ 60 kg
Arm Type: Other
Arm Title: Standard weight-based dosing
Arm 2: Standard weight-based dosing
Arm Description: Subjects in this arm will receive roxadustat 100 mg TIW for body weight &lt; 60 kg or 120 mg TIW for body weight ≥ 60 kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Part 2:
Arm Type: Other
Arm Title: Roxadustat
Arm Description: Subjects in this arm will receive roxadustat at different dose frequencies</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FG-4592</intervention_name>
    <description>Roxadustat will be dosed orally</description>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_label>Part 1 (2 arms) and Part 2</arm_group_label>
    <arm_group_label>Part 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. Chronic kidney disease with end-stage renal disease (ESRD) on either hemodialysis (HD)
        or peritoneal dialysis (PD)

        Exclusion Criteria:

          1. Positive for any of the following: human immunodeficiency virus (HIV), hepatitis B
             surface antigen (HBsAg), or anti-hepatitis C virus antibody (anti-HCV Ab).

          2. Cardiovascular risks such as: myocardial infarction, stroke, heart failure or a
             thromboembolic event (e.g., deep venous thrombosis or pulmonary embolism) within 26
             weeks prior to Day 1.

          3. History of malignancy, myelodysplastic syndrome, and multiple myeloma.

          4. Disease conditions that could impact red blood cell production.

          5. Recent blood loss (i.e clinically significant gastrointestinal bleeding).

          6. Women of childbearing potential and men with sexual partners of child bearing
             potential who are not using adequate contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chunrong Wang</last_name>
    <phone>+86 -21- 68810689</phone>
    <email>crwang@fibrogen.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Apple Zhao</last_name>
    <phone>+86 -21- 68810689</phone>
    <email>ggzhao@fibrogen.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230601</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <zip>730030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi Province</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Baotou</city>
        <state>Inner Mongolia Autonomous Region</state>
        <zip>014010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Chang chun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110122</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <zip>030001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610072</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Beijing</city>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Beijing</city>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Tianjin</city>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 8, 2019</study_first_submitted>
  <study_first_submitted_qc>August 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2019</study_first_posted>
  <last_update_submitted>August 15, 2019</last_update_submitted>
  <last_update_submitted_qc>August 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anemia</keyword>
  <keyword>Chronic Kidney Disease Dialysis</keyword>
  <keyword>hemoglobin</keyword>
  <keyword>End stage renal disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

